ASN
CLRB icon

Advisory Services Network’s Cellectar Biosciences CLRB Stock Holding History

Advisory Services Network’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33
Closed -$9K – 1414
2021
Q3 		$9K Buy
+33
New +$10.1K ﹤0.01% 1379

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Services Network's CLRB Position: Q4 2021 in Review

Advisory Services Network sold out of Cellectar Biosciences (CLRB) in Q4 2021, closing a stake of 33 shares — an estimated $9K sold.

Advisory Services Network first reported a position in CLRB in Q3 2021 and held it in 1 quarter. The position peaked at $9K in Q3 2021. 41 funds tracked by Wall St. Rank hold CLRB as of Q4 2021.

  • Advisory Services Network reported no remaining Cellectar Biosciences position as of Q4 2021 after selling out during the quarter.
  • Advisory Services Network sold 33 Cellectar Biosciences shares in Q4 2021, an estimated $9K.
  • Advisory Services Network first reported a position in Cellectar Biosciences in Q3 2021 and held it in 1 quarter.
  • Advisory Services Network's Cellectar Biosciences position peaked at $9K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2021.

Based on Advisory Services Network's 13F filing for Q4 2021, filed 14 Feb 2022.